Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794781 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00794781 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 55 participants.
The verdict
NCT00794781, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.
Interventions
- DRUG E6201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-06-22 |
| Est. Completion | 2015-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794781
The ClinicalTrials.gov registry entry for NCT00794781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E6201 is the first listed.
NCT00794781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794781 about?
NCT00794781 is a clinical study titled "A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.
What is the current status of trial NCT00794781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2008-06-22. Estimated completion is 2015-10-15.
What interventions are being tested in trial NCT00794781?
The interventions under investigation include: E6201 (DRUG).
Who is sponsoring clinical trial NCT00794781?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.